Study has major shortcomingsBMJ 2011; 342 doi: https://doi.org/10.1136/bmj.d3704 (Published 14 June 2011) Cite this as: BMJ 2011;342:d3704
- Fritz H Schroder, urologist1
- 1Erasmus Medical Centre, Rotterdam, Netherlands
Although Sandblom and colleagues’ study is the longest follow-up to date of prostate cancer screening,1 it has some major shortcomings.
(1) The group of men randomised to screening is small. Of the 1494 men, only 1161 participated in the initial screening (78%). Those who refused are apparently …